Pancreatic cancer: BRCA mutation and personalized treatment

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

(2014) T Golan et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian

(2014) Jacqueline Mersch et al.   CANCER

Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer

(2014) Shaohua Chen et al.   CANCER LETTERS

Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China

(2014) Jiang Long et al.   CANCER LETTERS

Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside

(2014) Helmut Oettle   CANCER TREATMENT REVIEWS

Pancreatic cancer: current standards, working towards a new therapeutic approach

(2014) Olugbenga Olowokure et al.   Expert Review of Anticancer Therapy

Familial pancreatic cancer: genetic advances

(2014) A. K. Rustgi   GENES & DEVELOPMENT

BRCA1, BRCA2, PALB2 and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

(2014) David B. Zhen et al.   GENETICS IN MEDICINE

Gemcitabine Induces Poly (ADP-Ribose) Polymerase-1 (PARP-1) Degradation through Autophagy in Pancreatic Cancer

(2014) Yufeng Wang et al.   PLoS One

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

(2014) Ciara C. O’Sullivan et al.   Frontiers in Oncology

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

(2013) J.-m. Lee et al.   ANNALS OF ONCOLOGY

Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin

(2013) Maryann Kwa et al.   ANNALS OF SURGICAL ONCOLOGY

Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry

(2013) E. Mocci et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer

(2013) L. Huang et al.   CARCINOGENESIS

High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions

(2013) A. L. Lucas et al.   CLINICAL CANCER RESEARCH

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

(2013) K. Yuan et al.   CLINICAL CANCER RESEARCH

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

(2012) J Iqbal et al.   BRITISH JOURNAL OF CANCER

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

(2012) C. C. Clark et al.   MOLECULAR CANCER THERAPEUTICS

Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity

(2012) Letizia Porcelli et al.   Molecular Oncology

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

(2011) Amir Sonnenblick et al.   CANCER BIOLOGY & THERAPY

Combinational therapy: New hope for pancreatic cancer?

(2011) Si Shi et al.   CANCER LETTERS

Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy

(2011) P. Ghiorzo et al.   Familial Cancer

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions

(2011) M. A. Lowery et al.   ONCOLOGIST

Absence of germline BRCA1 mutations in familial pancreatic cancer patients

(2010) Jennifer E. Axilbund et al.   CANCER BIOLOGY & THERAPY

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

(2010) Giuseppe Colucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature

(2009) Edward James et al.   ANTI-CANCER DRUGS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma

(2008) Cristina R. Ferrone et al.   JOURNAL OF CLINICAL ONCOLOGY

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

BRCA2 Mutations as a Universal Risk Factor for Pancreatic Cancer Has a Limited Role in Korean Ethnic Group

(2008) Jae Hee Cho et al.   PANCREAS

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA